Sarepta price target raised to $193 from $170 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Sarepta Therapeutics to $193 from $170 and keeps an Overweight rating on the shares. The company received on-time accelerated approval for Elevidys in anticipated 4-5 year-old Duchenne muscular dystrophy patients, with no major surprises on the label, the analyst tells investors in a research note. The firm says the wholesale acquisition cost price of $3.2M was slightly above expectations and the reimbursement discussion without outcome based approach could expedite the launch process. It expects high demand from both patients and physicians.